Abstract:Monoclonal antibodies (mAbs) are potent antiviral therapeutics that offer advantages, including post-exposure protection and protection for immunocompromised individuals. They can be modified to express antigen-specific paratopes in mono-specific, bi-specific, and multi-specific formats. Most available mAbs are approved as cancer and auto-immune medications. However, the utility of antiviral mAbs has been underscored by their successful deployment against many viruses, such as Ebola virus, human respiratory syncytial virus, human cytomegalovirus, influenza virus, and SARS-CoV-2 (1). This research topic, "Antiviral Monoclonal Antibody Therapies," highlights recent advances in mAb development and their utility against rapidly evolving viral pathogens. Production cost is a major hurdle that needs to be overcome to enable the widespread use of antiviral mAb treatments in low-income communities and countries. Shanmugaraj et al. (2) demonstrate that Nicotiana benthamiana is a powerful costeffective platform for producing mAbs in a scalable and affordable manner. This work describes the first report of SARS-CoV-2-specific mAbs produced in a plant expression system and characterizes their ability to retain neutralization properties in vitro.Another important factor to consider with antiviral mAb therapeutics, is the emergence of escape variants and their recalcitrance to vaccines and mAb treatments. Two studies in this research topic describe different approaches to solving this problem. One highlights the utility of bispecific mAbs, which can be engineered to increase the breadth of mAbs (3). The second delineates a simple and traditional hybridoma approach to mAb development and describes the development of a broadly neutralizing mouse anti-SARS-CoV-2-Spike mAb that neutralizes different SARS-CoV-2 variants(4). Broadly reactive mAbs that target conserved epitopes are attractive targets because they are less likely to result in escape mutations due to the lower fitness of generated mutants.Finally, Kim et al. (5) performed a retrospective multicenter study in South Korea to analyze the effectiveness of Regdanvimab, a SARS-CoV-2-specific mAb, in a hospitalized COVID-19 cohort. They found that compared to the group that received supportive care, patients that received Regdanvimab had reduced progression to severe disease. This was true for the overall study population but not for the patients infected with the SARS-CoV-2 delta variant. This work highlights the potential clinical benefits of antiviral mAb treatments, but also demonstrates that treatment regimens need to be optimized as new variants emerge.With this collection of research articles, we aim to highlight recent advances in the development and production of antiviral mAbs. As emerging and re-emerging viral pathogens continue to cause outbreaks in human populations, a need for effective, flexible, and affordable antiviral treatments is ever-present.

Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations

Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies: A monocentric experience

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19

Novel strategies in systemic and local administration of therapeutic monoclonal antibodies

Editorial: Antiviral monoclonal antibody therapies

A Short Update on the Use of Monoclonal Antibodies in COVID-19

Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses

Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19

Future of monoclonal antibodies in the treatment of hematologic malignancies

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment

Influences Shaping Clinicians' Monoclonal Antibody and Immune Checkpoint Inhibitor Preparation and Administration Management Practices: A Systematic Review

Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

Biopharmaceutics 4.0, Advanced Pre-Clinical Development of mRNA-Encoded Monoclonal Antibodies to Immunosuppressed Murine Models

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies

Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy

Antibodies to watch in 2024

Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development